Toward to a pre-symptomatic diagnosis of Alzheimer's

685 views

Published on

Mater's Thesis PowerPoint resume.

· Alzheimer's Disease
· Alzheimer's management
· Alzheimer's healthcare

Contact me via LinkedIn: www.linkedin.com/in/marcosdiazalzheimerresearch

Published in: Health & Medicine, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
685
On SlideShare
0
From Embeds
0
Number of Embeds
7
Actions
Shares
0
Downloads
14
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Toward to a pre-symptomatic diagnosis of Alzheimer's

  1. 1. Toward to a pre-symptomatic diagnosis ofToward to a pre-symptomatic diagnosis of Alzheimer’sAlzheimer’s Marcos Díaz Díaz Salamanca 2013
  2. 2. Index  Alzheimer’s Disease  Epidemiology and costs  Limitations of diagnosis criteria  Neuroimaging  Biomarkers  Current treatment for AE  Redefinition of disease
  3. 3. Alheimer’s Disease  Neurodegenerative disease  Unknown etiology  Etiopathogenic puzzle  Neurofibrillary tangles  Neuritic plaques (APP)  “Amyloid cascade”  ApoE
  4. 4. Epidemiology & costs  2010: more than half a million in Spain  2050: 1.5 million in Spain  2050: 115 million in the world  WHO: 215 thousand million €/year in dementia  Spain: 24.000€ / Europe: 54.000€  286h/month – 70h/week  Studies-researches:  Winsconsin  United Biosource
  5. 5. Limitations of diagnosis criteria  Screening tests in primary attention  DSM-IV  CIE-10  Mild cognitive impairment –MCI-  Cognitive reserve theory Too late
  6. 6. Neuroimaging  Computerized Tomography (CT)  Magnetic Resonance Imaging (MRI)  Single-Photon Emission Computed Tomography (SPECT)  Positron Emission Tomography (PET)  FDG  FDDNP  PIB  F-BAY94-9172  Florbetapir-F-18
  7. 7. Biomarkers  Genetic biomarkers  CSF biomarkers  β-amiloide peptide  Tau protein  T-tau  P-tau  β-amiloide & tau proteins combined  β-amiloide & tau proteins in MCI  Concomitant use of different biomarkers
  8. 8. Biomarkers
  9. 9. Current treatment for AE  Non-pharmacological therapy & concomitant therapy  AchE-Inhibitors & memantine  Monoclonal antibody (mab)  Bapineuzumab  Scarlet Road Study  Gantenerumab  Washington University Study  Gantenerumab  Solanezumab  LY2886721
  10. 10. Redefinition of disease  Clinical-biological model:  Alzheimer’s Disease  Alzheimer’s Dementia Dubois criteriaDubois criteria MCI or episodic memory debts for more than 6 months + CSF (P-tau o βA42) or MRI (entorhinal atrophy/amygdala) or PET (bilateral temporal hypometabolism or PET-PIB) or ApoE (4-4)
  11. 11. Toward to a pre-symptomatic diagnosis ofToward to a pre-symptomatic diagnosis of Alzheimer’sAlzheimer’s Marcos Díaz Diaz Salamanca 2013

×